Considering RAS mutations are observed in up to 93% of pancreatic cancer patients, the results of these studies strongly suggest ST6Gal1 as a downstream mediator of, and potential therapeutic target in, RAS-mediated pancreatic oncogenesis. This evidence concerns the gene ST6GAL1 and familial pancreatic carcinoma.